EA202090995A1 - Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 - Google Patents
Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1Info
- Publication number
- EA202090995A1 EA202090995A1 EA202090995A EA202090995A EA202090995A1 EA 202090995 A1 EA202090995 A1 EA 202090995A1 EA 202090995 A EA202090995 A EA 202090995A EA 202090995 A EA202090995 A EA 202090995A EA 202090995 A1 EA202090995 A1 EA 202090995A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- positive allosteric
- allosteric modulators
- receptors
- muscarine receptors
- polycyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к соединениям формулы (I) или к их изотопным формам, стереоизомерам, таутомерам или фармацевтически приемлемой соли (солям) в качестве положительных аллостерических модуляторов мускариновых рецепторов M1 (M1 PAM). Настоящее изобретение описывает получение, фармацевтическую композицию и применение соединения формулы (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741038173 | 2017-10-27 | ||
PCT/IB2018/058372 WO2019082140A1 (en) | 2017-10-27 | 2018-10-26 | POLYCYCLIC AMIDES AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090995A1 true EA202090995A1 (ru) | 2020-07-15 |
Family
ID=64362593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090995A EA202090995A1 (ru) | 2017-10-27 | 2018-10-26 | Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 |
Country Status (16)
Country | Link |
---|---|
US (1) | US11278530B2 (ru) |
EP (1) | EP3700895B1 (ru) |
JP (1) | JP7110338B2 (ru) |
KR (1) | KR102406885B1 (ru) |
CN (1) | CN111278814B (ru) |
AU (1) | AU2018354969B2 (ru) |
BR (1) | BR112020008050A2 (ru) |
CA (1) | CA3078164C (ru) |
EA (1) | EA202090995A1 (ru) |
IL (1) | IL273885B (ru) |
MA (1) | MA50464A (ru) |
MX (1) | MX2020004339A (ru) |
NZ (1) | NZ763341A (ru) |
SG (1) | SG11202003471XA (ru) |
WO (1) | WO2019082140A1 (ru) |
ZA (1) | ZA202002058B (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102017220539A1 (de) | 2017-11-17 | 2019-05-23 | Zf Friedrichshafen Ag | Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät |
WO2020067456A1 (ja) * | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 複素環化合物 |
EP3858823A4 (en) * | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | CONDENSED CYCLIC COMPOUND |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754220B2 (en) * | 2009-11-20 | 2014-06-17 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide M1 receptor positive allosteric modulators |
PL2512243T3 (pl) | 2009-12-17 | 2016-09-30 | Pozytywne modulatory allosteryczne receptora amidu chinoliny m1 | |
WO2011149801A1 (en) * | 2010-05-28 | 2011-12-01 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
US8815902B2 (en) * | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
JP6211509B2 (ja) * | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
GB201317363D0 (en) * | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
WO2015080904A1 (en) * | 2013-11-27 | 2015-06-04 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
CA2930961A1 (en) * | 2014-01-22 | 2015-07-30 | F. Hoffmann-La Roche Ag | Fluoro-naphthyl derivatives |
WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
DK3303331T3 (en) | 2015-06-08 | 2019-04-23 | Suven Life Sciences Ltd | MUSCARIN M1 RECEPTOR-POSITIVE ALLOSTER MODULATORS |
DK3347349T3 (da) | 2015-09-10 | 2019-10-28 | Suven Life Sciences Ltd | Fluorindolderivater som muskarin m1-receptor-positive allosteriske modulatorer |
WO2017123482A1 (en) | 2016-01-14 | 2017-07-20 | Merck Sharp & Dohme Corp. | Dihydropyrido quinazoline m1 receptor positive allosteric modulators |
EP3416639B1 (en) * | 2016-02-16 | 2022-06-08 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
WO2017155816A1 (en) * | 2016-03-09 | 2017-09-14 | Merck Sharp & Dohme Corp. | Quinazoline compounds useful as m1 receptor positive allosteric modulators |
JP6860551B2 (ja) | 2016-03-11 | 2021-04-14 | 武田薬品工業株式会社 | 芳香環化合物 |
ES2824495T3 (es) * | 2016-09-02 | 2021-05-12 | Suven Life Sciences Ltd | Moduladores alostéricos positivos del receptor muscarínico M1 |
US10899759B2 (en) * | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
PT3643718T (pt) * | 2017-06-20 | 2023-10-26 | Takeda Pharmaceuticals Co | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 |
BR112020007606A2 (pt) * | 2017-10-18 | 2020-09-29 | Suven Life Sciences Limited | composto, composição farmacêutica, uso do composto e da composição farmacêutica e combinação |
EA202191046A1 (ru) * | 2018-10-17 | 2021-07-12 | Сувен Лайф Сайенсиз Лимитед | Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1 |
US20200131180A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
US20200131159A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
-
2018
- 2018-10-26 BR BR112020008050-0A patent/BR112020008050A2/pt unknown
- 2018-10-26 KR KR1020207014244A patent/KR102406885B1/ko active IP Right Grant
- 2018-10-26 CA CA3078164A patent/CA3078164C/en active Active
- 2018-10-26 EA EA202090995A patent/EA202090995A1/ru unknown
- 2018-10-26 NZ NZ763341A patent/NZ763341A/en unknown
- 2018-10-26 CN CN201880069620.7A patent/CN111278814B/zh active Active
- 2018-10-26 SG SG11202003471XA patent/SG11202003471XA/en unknown
- 2018-10-26 AU AU2018354969A patent/AU2018354969B2/en active Active
- 2018-10-26 EP EP18804707.0A patent/EP3700895B1/en active Active
- 2018-10-26 WO PCT/IB2018/058372 patent/WO2019082140A1/en unknown
- 2018-10-26 US US16/755,864 patent/US11278530B2/en active Active
- 2018-10-26 MX MX2020004339A patent/MX2020004339A/es unknown
- 2018-10-26 MA MA050464A patent/MA50464A/fr unknown
- 2018-10-26 JP JP2020521904A patent/JP7110338B2/ja active Active
-
2020
- 2020-04-07 IL IL273885A patent/IL273885B/en active IP Right Grant
- 2020-05-04 ZA ZA2020/02058A patent/ZA202002058B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11278530B2 (en) | 2022-03-22 |
MA50464A (fr) | 2021-06-02 |
AU2018354969A1 (en) | 2020-04-23 |
ZA202002058B (en) | 2021-04-28 |
CA3078164A1 (en) | 2019-05-02 |
SG11202003471XA (en) | 2020-05-28 |
IL273885A (en) | 2020-05-31 |
CN111278814B (zh) | 2022-10-28 |
JP2021500338A (ja) | 2021-01-07 |
IL273885B (en) | 2021-01-31 |
JP7110338B2 (ja) | 2022-08-01 |
CA3078164C (en) | 2022-11-15 |
KR20200074177A (ko) | 2020-06-24 |
BR112020008050A2 (pt) | 2020-11-03 |
WO2019082140A1 (en) | 2019-05-02 |
AU2018354969B2 (en) | 2020-09-17 |
CN111278814A (zh) | 2020-06-12 |
EP3700895B1 (en) | 2021-09-22 |
MX2020004339A (es) | 2020-08-03 |
KR102406885B1 (ko) | 2022-06-08 |
EP3700895A1 (en) | 2020-09-02 |
US20200297703A1 (en) | 2020-09-24 |
NZ763341A (en) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
EA202090486A2 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201891179A1 (ru) | N-замещенные индольные производные в качестве модуляторов pge2 рецепторов | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
EA201992679A1 (ru) | N-замещенные индольные производные | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
EA202091256A1 (ru) | Новые антагонисты рецептора брадикинина | |
PH12018500377A1 (en) | Novel annelated benzamides | |
EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
EA202090995A1 (ru) | Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 | |
EA201692300A1 (ru) | Производные карбоксамида | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
EA202090925A1 (ru) | Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 | |
EA201692090A1 (ru) | Полициклические активаторы herg | |
EA202191046A1 (ru) | Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1 | |
EA202091302A1 (ru) | Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
EA201990534A1 (ru) | Позитивные аллостерические модуляторы мускариновых m1–рецепторов | |
EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора |